| |
Fig. 2. Xenopus laevis embryos injected with antisense ISWI RNA or anti-ISWI morpholino. A–C: Embryos photographed when control-injected embryos reached approximately stage 20–22. Embryos were injected with either 80 ng control morpholino (A), 4 ng of antisense ISWI RNA (B; representative of phenotype observed for injection of 2 and 10 ng as well) or 80 ng anti-ISWI morpholino (C; also representative of other of 40 and 160 ng morpholino inections). D–F: Whole mount in situ hybridization of stage 12 (D), 13 (E) and 14 (F) embryos with the ISWI probe described in Fig. 1, showing early differential expression of ISWI. These are dorsal views with the anterior to the left side of the figure. Black dashes indicate the midline for each embryo. G–H: Embryos injected with 80 ng of either control morpholino (G) or anti-ISWI morpholino (H). The embryo in H represents one of the very few embryos to survive the initial gastrulation defect at high morpholino concentrations. I: Western blot showing reduced levels of ISWI protein in embryos injected with 10 ng of ISWI antisense RNA (left), or 80 ng anti-ISWI morpholino (right), compared to control embryos injected with nanopure water or control morpholino (80 ng), respectively. Antibody against E-cadherin (E-cad) is used as a loading control. |
